FY2025 Earnings Forecast for FDMT Issued By Leerink Partnrs

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Investment analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for 4D Molecular Therapeutics in a research note issued to investors on Monday, November 10th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($3.64) per share for the year, down from their previous forecast of ($3.59). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics’ Q4 2025 earnings at ($0.60) EPS and FY2026 earnings at ($2.83) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%.

A number of other equities research analysts have also weighed in on FDMT. Royal Bank Of Canada boosted their target price on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday. Barclays lowered their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 7th. Leerink Partners reissued an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Finally, Chardan Capital upped their target price on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $28.70.

4D Molecular Therapeutics Stock Down 2.3%

Shares of NASDAQ FDMT traded down $0.25 during midday trading on Thursday, hitting $10.72. The stock had a trading volume of 103,297 shares, compared to its average volume of 857,287. The company has a market cap of $500.74 million, a P/E ratio of -2.87 and a beta of 2.96. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34. The business’s 50 day moving average is $9.18 and its 200-day moving average is $6.18.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the sale, the insider directly owned 3,594 shares of the company’s stock, valued at approximately $43,128. The trade was a 42.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 9,128 shares of company stock worth $92,100 in the last ninety days. Company insiders own 9.60% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds have recently modified their holdings of FDMT. Farther Finance Advisors LLC increased its position in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares during the last quarter. Abich Financial Wealth Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at about $80,000. Inscription Capital LLC bought a new stake in 4D Molecular Therapeutics during the third quarter worth approximately $94,000. Impact Partnership Wealth LLC purchased a new stake in 4D Molecular Therapeutics during the third quarter valued at approximately $96,000. Finally, Quadrature Capital Ltd bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $42,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.